Search research articles
Contact Us
Filters
Showing results (181-190 of 214) with videos related to
Page
of 22
Sort By:
Lancet (London, England)
|
July 8, 1998
Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma
J J Grob, B Dreno, P de la Salmonière, et al.
ESMO Open
|
May 14, 2024
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study
S P D'Angelo, C Lebbé, L Mortier, et al.
Annales De Dermatologie Et De Venereologie
|
March 9, 2006
[Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations]
S Négrier, P Saiag, B Guillot, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 25, 2021
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition
J J Grob, A Guminski, J Malvehy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 23, 2021
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas
J J Grob, C Gaudy-Marqueste, A Guminski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2022
Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2014
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
J-J Grob, M M Amonkar, S Martin-Algarra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2021
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
M R Middleton, J J Grob, N Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)
P Saiag, R Gutzmer, P A Ascierto, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 214) with videos related to
Sort By:
Page
of 22
Lancet (London, England)
|
July 8, 1998
Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma
J J Grob, B Dreno, P de la Salmonière, et al.
ESMO Open
|
May 14, 2024
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study
S P D'Angelo, C Lebbé, L Mortier, et al.
Annales De Dermatologie Et De Venereologie
|
March 9, 2006
[Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the 1995 Consensus Conference and the 1998 Standards, Options, and Recommendations]
S Négrier, P Saiag, B Guillot, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 25, 2021
Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition
J J Grob, A Guminski, J Malvehy, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 23, 2021
Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas
J J Grob, C Gaudy-Marqueste, A Guminski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2022
Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2014
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
J-J Grob, M M Amonkar, S Martin-Algarra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 22, 2021
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
B G M Hughes, E Munoz-Couselo, L Mortier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
M R Middleton, J J Grob, N Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 10, 2016
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)
P Saiag, R Gutzmer, P A Ascierto, et al.
Page
of 22